<DOC>
	<DOCNO>NCT01149798</DOCNO>
	<brief_summary>This phase II trial assumption abraxane cisplatin combination therapy efficacy metastatic breast cancer .</brief_summary>
	<brief_title>A Combination Abraxane Cisplatin Metastatic Breast Cancer</brief_title>
	<detailed_description>The rationale combination Abraxane cisplatin include either drug antitumor activity ; different mechanism ; cross-resistance document , preclinical evidence indicate synergistic effect two agent . This phase II study undertaken evaluate combination cisplatin weekly abraxane term efficacy safety MBC patient .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<criteria>Subject must fulfill follow condition characteristic order consider study enrollment : 1 . Written inform consent prior study specific screening procedure , understand patient right withdraw study time without prejudice . 2 . At least one measurable disease per Response Evaluation Criteria Solid Tumors ( RECIST ) . 3 . Histopathologically cytologically confirm breast cancer . 4 . Female age ≥18 year . 5 . Prior taxane platinum treatment allow . However , drug interval longer 12 month adjuvant/neoadjuvant set three month MBC patient obtain ORR taxane platinumcontaining regimen . 6 . The lab value within 2 week prior trial meet : PLT ≥100,000/mm3 ANC≥2000/mm3 HB≥80g/L Total bilirubin &lt; upper limit normal level（UNL , &lt; 1.5 x UNL patient liver metastasis ) ALT/AST &lt; 1.5 x UNL ( &lt; 2.5 x UNL patient liver metastasis ) AKP &lt; 5 x UNL ( except patient bone metastasis ) Serum creatinine &lt; UNL 7 . ECOG performance status 0 , 1 2 . 8 . A life expectancy 3 month . 1 . Pregnant breastfeed woman . 2 . Positive serum pregnancy test . 3 . Unwilling use medically acceptable form contraception , except surgically sterile least 1 year postmenopausal . 4 . Uncontrolled brain metastasis . Patients brain metastasis must locally treated disease must stable least one month time enrol . 5 . Meningeal metastasis . 6 . Radiotherapy within 4 week precede study treatment start . 7 . Incomplete recovery effect major surgery . 8 . Prior hormonal treatment allow must discontinue 14 day prior study entry . 9 . Participation investigational drug study within 4 week precede treatment start . 10 . Blood transfusion growth factor aid hematological recovery within 2 week prior study treatment start . 11 . Significant medical condition would make treatment followup protocol difficult problematic opinion treat oncologist . 12 . Concurrent malignancy sit previous cancer within last 5 year , exception adequately treat situ carcinoma cervix uteri basal squamous cell carcinoma skin contralateral breast cancer . 13 . Serious uncontrolled intercurrent infection . 14 . Poor compliance .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>metastatic breast cancer</keyword>
	<keyword>combine chemotherapy</keyword>
</DOC>